AMICUS THERAPEUTICS, INC. Interest Expense Nonoperating
AMICUS THERAPEUTICS, INC. reported Interest Expense Nonoperating of $46.16 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-02-20
- AMICUS THERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $11.43M, a 4.43% decline year-over-year.
- AMICUS THERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $11.71M, a 7.73% decline year-over-year.
- AMICUS THERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2025-06-30 was $11.56M, a 7.57% decline year-over-year.
- AMICUS THERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2025-03-31 was $11.46M, a 7.89% decline year-over-year.
- AMICUS THERAPEUTICS, INC. interest expense nonoperating for fiscal 2025 was $46.16M, a 6.93% decline from fiscal 2024.
- AMICUS THERAPEUTICS, INC. interest expense nonoperating for fiscal 2024 was $49.60M, a 1.10% decline from fiscal 2023.
- AMICUS THERAPEUTICS, INC. interest expense nonoperating for fiscal 2023 was $50.15M, a 35.10% increase from fiscal 2022.
- AMICUS THERAPEUTICS, INC. interest expense nonoperating for fiscal 2022 was $37.12M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2025-12-31 | $11.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $23.14M derived: sum of 2 quarters · filed 2026-02-20 | $34.70M derived: sum of 3 quarters · filed 2026-02-20 | $46.16M 10-K · filed 2026-02-20 |
| 2025-09-30 | $11.71M 10-Q · filed 2025-11-04 | $23.28M derived: sum of 2 quarters · filed 2025-11-04 | $34.73M 10-Q · filed 2025-11-04 | $46.69M derived: sum of 4 quarters · filed 2026-02-20 |
| 2025-06-30 | $11.56M 10-Q · filed 2025-07-31 | $23.02M 10-Q · filed 2025-07-31 | $34.98M derived: sum of 3 quarters · filed 2026-02-20 | $47.67M derived: sum of 4 quarters · filed 2026-02-20 |
| 2025-03-31 | $11.46M 10-Q · filed 2025-05-01 | $23.41M derived: sum of 2 quarters · filed 2026-02-20 | $36.10M derived: sum of 3 quarters · filed 2026-02-20 | $48.62M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-12-31 | $11.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $24.65M derived: sum of 2 quarters · filed 2026-02-20 | $37.16M derived: sum of 3 quarters · filed 2026-02-20 | $49.60M 10-K · filed 2026-02-20 |
| 2024-09-30 | $12.69M 10-Q · filed 2025-11-04 | $25.20M derived: sum of 2 quarters · filed 2025-11-04 | $37.64M 10-Q · filed 2025-11-04 | $50.47M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-06-30 | $12.51M 10-Q · filed 2025-07-31 | $24.95M 10-Q · filed 2025-07-31 | $37.77M derived: sum of 3 quarters · filed 2026-02-20 | $50.76M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-03-31 | $12.44M 10-Q · filed 2025-05-01 | $25.26M derived: sum of 2 quarters · filed 2026-02-20 | $38.25M derived: sum of 3 quarters · filed 2026-02-20 | $50.74M derived: sum of 4 quarters · filed 2026-02-20 |
| 2023-12-31 | $12.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $25.81M derived: sum of 2 quarters · filed 2026-02-20 | $38.30M derived: sum of 3 quarters · filed 2026-02-20 | $50.15M 10-K · filed 2026-02-20 |
| 2023-09-30 | $12.99M 10-Q · filed 2024-11-06 | $25.48M derived: sum of 2 quarters · filed 2024-11-06 | $37.32M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $12.49M 10-Q · filed 2024-08-08 | $24.34M 10-Q · filed 2024-08-08 | ||
| 2022-12-31 | $37.12M 10-K · filed 2025-02-19 |